The Plasma Contact System 2.0

 

 Buy Article Permissions and Reprints

ABSTRACT

The contact system is a protease cascade that is initiated by factor XII activation on cardiovascular cells. The system starts procoagulant and proinflammatory reactions, via the intrinsic pathway of coagulation and the kallikrein-kinin system, respectively. The biochemistry of the contact system in vitro is well understood. However, activators of the system in vivo and their contributions to disease states have remained enigmatic. Recent experimental and clinical data have identified misfolded proteins, collagens, and polyphosphates as the long-sought activators of the contact system in vivo. Here we present an overview about contact system activators and their contributions to health and pathology.

REFERENCES

• 1 Renné T, Dedio J, Meijers J C, Chung D, Müller-Esterl W. Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2.  J Biol Chem. 1999;  274 (36) 25777-25784
  CrossrefPubMedGoogle Scholar
• 2 Müller F, Renné T. Novel roles for factor XII-driven plasma contact activation system.  Curr Opin Hematol. 2008;  15 (5) 516-521
  CrossrefPubMedGoogle Scholar
• 3 Revak S D, Cochrane C G, Bouma B N, Griffin J H. Surface and fluid phase activities of two forms of activated Hageman factor produced during contact activation of plasma.  J Exp Med. 1978;  147 (3) 719-729
  CrossrefPubMedGoogle Scholar
• 4 Renné T, Schuh K, Müller-Esterl W. Local bradykinin formation is controlled by glycosaminoglycans.  J Immunol. 2005;  175 (5) 3377-3385
  CrossrefPubMedGoogle Scholar
• 5 Kluft C, Trumpi-Kalshoven M M, Jie A F, Veldhuyzen-Stolk E C. Factor XII-dependent fibrinolysis: a double function of plasma kallikrein and the occurrence of a previously undescribed factor XII- and kallikrein-dependent plasminogen proactivator.  Thromb Haemost. 1979;  41 (4) 756-773
  PubMedGoogle Scholar
• 6 Ghebrehiwet B, Silverberg M, Kaplan A P. Activation of the classical pathway of complement by Hageman factor fragment.  J Exp Med. 1981;  153 (3) 665-676
  CrossrefPubMedGoogle Scholar
• 7 Renné T, Gailani D. Role of factor XII in hemostasis and thrombosis: clinical implications.  Expert Rev Cardiovasc Ther. 2007;  5 (4) 733-741
  CrossrefPubMedGoogle Scholar
• 8 Gailani D, Broze Jr G J. Factor XI activation in a revised model of blood coagulation.  Science. 1991;  253 (5022) 909-912
  CrossrefPubMedGoogle Scholar
• 9 Pedicord D L, Seiffert D, Blat Y. Feedback activation of factor XI by thrombin does not occur in plasma.  Proc Natl Acad Sci U S A. 2007;  104 (31) 12855-12860
  CrossrefPubMedGoogle Scholar
• 10 Kravtsov D V, Matafonov A, Tucker E I et al.. Factor XI contributes to thrombin generation in the absence of factor XII.  Blood. 2009;  114 (2) 452-458
  CrossrefPubMedGoogle Scholar
• 11 Maas C, Meijers J C, Marquart J A et al.. Activated factor V is a cofactor for the activation of factor XI by thrombin in plasma.  Proc Natl Acad Sci U S A. 2010;  107 (20) 9083-9087
  CrossrefPubMedGoogle Scholar
• 12 Schulze-Topphoff U, Prat A, Prozorovski T et al.. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system.  Nat Med. 2009;  15 (7) 788-793
  CrossrefPubMedGoogle Scholar
• 13 Leeb-Lundberg L M, Marceau F, Müller-Esterl W, Pettibone D J, Zuraw B L. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences.  Pharmacol Rev. 2005;  57 (1) 27-77
  CrossrefPubMedGoogle Scholar
• 14 Renné T, Dedio J, David G, Müller-Esterl W. High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells.  J Biol Chem. 2000;  275 (43) 33688-33696
  CrossrefPubMedGoogle Scholar
• 15 Stavrou E, Schmaier A H. Factor XII: what does it contribute to our understanding of the physiology and pathophysiology of hemostasis & thrombosis.  Thromb Res. 2010;  125 (3) 210-215
  CrossrefPubMedGoogle Scholar
• 16 Nielsen V G. Corn trypsin inhibitor decreases tissue-type plasminogen activator-mediated fibrinolysis of human plasma.  Blood Coagul Fibrinolysis. 2009;  20 (3) 191-196
  CrossrefPubMedGoogle Scholar
• 17 Brown N J, Gainer J V, Stein C M, Vaughan D E. Bradykinin stimulates tissue plasminogen activator release in human vasculature.  Hypertension. 1999;  33 (6) 1431-1435
  CrossrefPubMedGoogle Scholar
• 18 Levi M, Hack C E, de Boer J P, Brandjes D P, Büller H R, ten Cate J W. Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo.  J Clin Invest. 1991;  88 (4) 1155-1160
  CrossrefPubMedGoogle Scholar
• 19 Lund L R, Green K A, Stoop A A et al.. Plasminogen activation independent of uPA and tPA maintains wound healing in gene-deficient mice.  EMBO J. 2006;  25 (12) 2686-2697
  CrossrefPubMedGoogle Scholar
• 20 Lilla J N, Werb Z. Mast cells contribute to the stromal microenvironment in mammary gland branching morphogenesis.  Dev Biol. 2010;  337 (1) 124-133
  CrossrefPubMedGoogle Scholar
• 21 Lilla J N, Joshi R V, Craik C S, Werb Z. Active plasma kallikrein localizes to mast cells and regulates epithelial cell apoptosis, adipocyte differentiation, and stromal remodeling during mammary gland involution.  J Biol Chem. 2009;  284 (20) 13792-13803
  CrossrefPubMedGoogle Scholar
• 22 Ratnoff O D, Colopy J E. A familial hemorrhagic trait associated with a deficiency of a clot-promoting fraction of plasma.  J Clin Invest. 1955;  34 (4) 602-613
  CrossrefPubMedGoogle Scholar
• 23 Ratnoff O D, Busse Jr R J, Sheon R P. The demise of John Hageman.  N Engl J Med. 1968;  279 (14) 760-761
  CrossrefPubMedGoogle Scholar
• 24 Cushman M, O'Meara E S, Folsom A R, Heckbert S R. Coagulation factors IX through XIII and the risk of future venous thrombosis: the Longitudinal Investigation of Thromboembolism Etiology.  Blood. 2009;  114 (14) 2878-2883
  CrossrefPubMedGoogle Scholar
• 25 Müller F, Mutch N J, Schenk W A et al.. Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo.  Cell. 2009;  139 (6) 1143-1156
  CrossrefPubMedGoogle Scholar
• 26 Hathaway W E, Wuepper K D, Weston W L et al.. Clinical and physiologic studies of two siblings with prekallikrein (Fletcher factor) deficiency.  Am J Med. 1976;  60 (5) 654-664
  CrossrefPubMedGoogle Scholar
• 27 Pavletic A. Angioedema of the intestine.  N Engl J Med. 1996;  335 (20) 1534 author reply 1535
  CrossrefPubMedGoogle Scholar
• 28 Cichon S, Martin L, Hennies H C et al.. Increased activity of coagulation factor XII (Hageman factor) causes hereditary angioedema type III.  Am J Hum Genet. 2006;  79 (6) 1098-1104
  CrossrefPubMedGoogle Scholar
• 29 Nielsen E W, Johansen H T, Høgåsen K, Wuillemin W, Hack C E, Mollnes T E. Activation of the complement, coagulation, fibrinolytic and kallikrein-kinin systems during attacks of hereditary angioedema.  Scand J Immunol. 1996;  44 (2) 185-192
  CrossrefPubMedGoogle Scholar
• 30 Lehmann A. Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery.  Expert Opin Biol Ther. 2008;  8 (8) 1187-1199
  CrossrefPubMedGoogle Scholar
• 31 Marqués L, Domingo D, Maravall F J, Clotet J. Short-term prophylactic treatment of hereditary angioedema with icatibant.  Allergy. 2010;  65 (1) 137-138
  CrossrefPubMedGoogle Scholar
• 32 Wright F L, Hua H T, Velmahos G, Thoman D, Demitriades D, Rhee P M. Intracorporeal use of the hemostatic agent QuickClot in a coagulopathic patient with combined thoracoabdominal penetrating trauma.  J Trauma. 2004;  56 (1) 205-208
  CrossrefPubMedGoogle Scholar
• 33 Kheirabadi B S, Mace J E, Terrazas I B et al.. Safety evaluation of new hemostatic agents, smectite granules, and kaolin-coated gauze in a vascular injury wound model in swine.  J Trauma. 2010;  68 (2) 269-278
  CrossrefPubMedGoogle Scholar
• 34 Devlin J J, Kircher S, Kozen B G, Littlejohn L F, Johnson A S. Comparison of ChitoFlex(R), CELOX, and QuikClot(R) in Control of Hemorrhage.  J Emerg Med. 2009; April 1;  (Epub ahead of print)
  PubMedGoogle Scholar
• 35 Samuel M, Pixley R A, Villanueva M A, Colman R W, Villanueva G B. Human factor XII (Hageman factor) autoactivation by dextran sulfate. Circular dichroism, fluorescence, and ultraviolet difference spectroscopic studies.  J Biol Chem. 1992;  267 (27) 19691-19697
  PubMedGoogle Scholar
• 36 Siebeck M, Cheronis J C, Fink E et al.. Dextran sulfate activates contact system and mediates arterial hypotension via B2 kinin receptors.  J Appl Physiol. 1994;  77 (6) 2675-2680
  CrossrefPubMedGoogle Scholar
• 37 Kishimoto T K, Viswanathan K, Ganguly T et al.. Contaminated heparin associated with adverse clinical events and activation of the contact system.  N Engl J Med. 2008;  358 (23) 2457-2467
  CrossrefPubMedGoogle Scholar
• 38 Hojima Y, Cochrane C G, Wiggins R C, Austen K F, Stevens R L. In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E.  Blood. 1984;  63 (6) 1453-1459
  PubMedGoogle Scholar
• 39 Ratnoff O D, Saito H. The evolution of clot-promoting and amidolytic activities in mixtures of Hageman factor (factor XII) and ellagic acid.  J Lab Clin Med. 1982;  100 (2) 248-260
  PubMedGoogle Scholar
• 40 Girolami A, Cliffton E E. Hypercoagulable state induced in humans by the intravenous administration of purified ellagic acid.  Thromb Diath Haemorrh. 1967;  17 (1–2) 165-175
  PubMedGoogle Scholar
• 41 Iatridis S G, Iatridis P G, Ferguson J H. Effects of ellagic acid upon the human fibrinolytic system.  Thromb Diath Haemorrh. 1966;  16 (3) 656-667
  PubMedGoogle Scholar
• 42 Bhargava U C, Westfall B A. The mechanism of blood pressure depression by ellagic acid.  Proc Soc Exp Biol Med. 1969;  132 (2) 754-756
  PubMedGoogle Scholar
• 43 Kleinschnitz C, Stoll G, Bendszus M et al.. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis.  J Exp Med. 2006;  203 (3) 513-518
  CrossrefPubMedGoogle Scholar
• 44 Merkulov S, Zhang W M, Komar A A et al.. Deletion of murine kininogen gene 1 (mKng1) causes loss of plasma kininogen and delays thrombosis.  Blood. 2008;  111 (3) 1274-1281
  PubMedGoogle Scholar
• 45 Renné T, Pozgajová M, Grüner S et al.. Defective thrombus formation in mice lacking coagulation factor XII.  J Exp Med. 2005;  202 (2) 271-281
  CrossrefPubMedGoogle Scholar
• 46 Gailani D, Renné T. Intrinsic pathway of coagulation and arterial thrombosis.  Arterioscler Thromb Vasc Biol. 2007;  27 (12) 2507-2513
  CrossrefPubMedGoogle Scholar
• 47 Gailani D, Renné T. The intrinsic pathway of coagulation: a target for treating thromboembolic disease?.  J Thromb Haemost. 2007;  5 (6) 1106-1112
  CrossrefPubMedGoogle Scholar
• 48 Gebbink M F, Bouma B, Maas C, Bouma B N. Physiological responses to protein aggregates: fibrinolysis, coagulation and inflammation (new roles for old factors).  FEBS Lett. 2009;  583 (16) 2691-2699
  CrossrefPubMedGoogle Scholar
• 49 Bergamaschini L, Donarini C, Gobbo G, Parnetti L, Gallai V. Activation of complement and contact system in Alzheimer's disease.  Mech Ageing Dev. 2001;  122 (16) 1971-1983
  CrossrefPubMedGoogle Scholar
• 50 Bergamaschini L, Canziani S, Bottasso B, Cugno M, Braidotti P, Agostoni A. Alzheimer's beta-amyloid peptides can activate the early components of complement classical pathway in a C1q-independent manner.  Clin Exp Immunol. 1999;  115 (3) 526-533
  CrossrefPubMedGoogle Scholar
• 51 Maas C, Govers-Riemslag J W, Bouma B et al.. Misfolded proteins activate factor XII in humans, leading to kallikrein formation without initiating coagulation.  J Clin Invest. 2008;  118 (9) 3208-3218
  PubMedGoogle Scholar
• 52 Bouma B, Maas C, Hazenberg B P, Lokhorst H M, Gebbink M F. Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses.  J Thromb Haemost. 2007;  5 (6) 1139-1142
  CrossrefPubMedGoogle Scholar
• 53 Schmaier A H. The elusive physiologic role of factor XII.  J Clin Invest. 2008;  118 (9) 3006-3009
  PubMedGoogle Scholar
• 54 Herwald H, Renné T, Meijers J C et al.. Mapping of the discontinuous kininogen binding site of prekallikrein. A distal binding segment is located in the heavy chain domain A4.  J Biol Chem. 1996;  271 (22) 13061-13067
  CrossrefPubMedGoogle Scholar
• 55 Renné T, Gailani D, Meijers J C, Müller-Esterl W. Characterization of the H-kininogen-binding site on factor XI: a comparison of factor XI and plasma prekallikrein.  J Biol Chem. 2002;  277 (7) 4892-4899
  CrossrefPubMedGoogle Scholar
• 56 Citarella F, Ravon D M, Pascucci B, Felici A, Fantoni A, Hack C E. Structure/function analysis of human factor XII using recombinant deletion mutants. Evidence for an additional region involved in the binding to negatively charged surfaces.  Eur J Biochem. 1996;  238 (1) 240-249
  CrossrefPubMedGoogle Scholar
• 57 Citarella F, te Velthuis H, Helmer-Citterich M, Hack C E. Identification of a putative binding site for negatively charged surfaces in the fibronectin type II domain of human factor XII—an immunochemical and homology modeling approach.  Thromb Haemost. 2000;  84 (6) 1057-1065
  Article in Thieme ConnectPubMedGoogle Scholar
• 58 Maas C, Schiks B, Strangi R D et al.. Identification of fibronectin type I domains as amyloid-binding modules on tissue-type plasminogen activator and three homologs.  Amyloid. 2008;  15 (3) 166-180
  CrossrefPubMedGoogle Scholar
• 59 Wilner G D, Nossel H L, LeRoy E C. Activation of Hageman factor by collagen.  J Clin Invest. 1968;  47 (12) 2608-2615
  CrossrefPubMedGoogle Scholar
• 60 van der Meijden P E, Munnix I C, Auger J M et al.. Dual role of collagen in factor XII-dependent thrombus formation.  Blood. 2009;  114 (4) 881-890
  CrossrefPubMedGoogle Scholar
• 61 Reininger A J, Bernlochner I, Penz S M et al.. A 2-step mechanism of arterial thrombus formation induced by human atherosclerotic plaques.  J Am Coll Cardiol. 2010;  55 (11) 1147-1158
  CrossrefPubMedGoogle Scholar
• 62 Mao Y, Getz T M, Jin J, Kunapuli S P. Coagulation factor XIIa activates platelets and is the physiological agonist of protease-activated receptor 3.  Blood. 2009;  114 770A
  PubMedGoogle Scholar
• 63 Castaldi P A, Larrieu M J, Caen J. Availability of platelet factor 3 and activation of factor XII in thrombasthenia.  Nature. 1965;  207 (995) 422-424
  CrossrefPubMedGoogle Scholar
• 64 Johne J, Blume C, Benz P M et al.. Platelets promote coagulation factor XII-mediated proteolytic cascade systems in plasma.  Biol Chem. 2006;  387 (2) 173-178
  CrossrefPubMedGoogle Scholar
• 65 Bäck J, Sanchez J, Elgue G, Ekdahl K N, Nilsson B. Activated human platelets induce factor XIIa-mediated contact activation.  Biochem Biophys Res Commun. 2010;  391 (1) 11-17
  CrossrefPubMedGoogle Scholar
• 66 Ruiz F A, Lea C R, Oldfield E, Docampo R. Human platelet dense granules contain polyphosphate and are similar to acidocalcisomes of bacteria and unicellular eukaryotes.  J Biol Chem. 2004;  279 (43) 44250-44257
  CrossrefPubMedGoogle Scholar
• 67 Smith S A, Mutch N J, Baskar D, Rohloff P, Docampo R, Morrissey J H. Polyphosphate modulates blood coagulation and fibrinolysis.  Proc Natl Acad Sci U S A. 2006;  103 (4) 903-908
  CrossrefPubMedGoogle Scholar
• 68 Smith S A, Morrissey J H. Polyphosphate as a general procoagulant agent.  J Thromb Haemost. 2008;  6 (10) 1750-1756
  CrossrefPubMedGoogle Scholar

Thomas Renné

Department of Molecular Medicine and Surgery, Karolinska Institutet, Karolinska University Hospital Solna (L1:00)

SE-171 76 Stockholm, Sweden

Email: thomas@renne.net